This inventor holds 1 USPTO granted patent. Top assignee: Hisamitsu Pharmaceutical Company, Inc.. Active years: 1982.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1982
Title: Hidetoshi Amano: Innovator in Antiallergic Compounds
Introduction
Hidetoshi Amano is a notable inventor based in Tosu, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in developing compounds that address allergic conditions. His work is recognized for its potential therapeutic applications in treating various allergy-related diseases.
Latest Patents
Amano holds a patent for "Novel anthranilic acid derivatives." This patent describes a series of compounds characterized by a general formula that includes various substituents such as halogen atoms, alkoxyl groups, and alkyl groups. These derivatives and their pharmaceutically acceptable salts exhibit strong antiallergic actions, making them useful in treating conditions like asthma, hay fever, urticaria, and atopic dermatitis. The patent also outlines an antiallergic composition and a method for alleviating allergy-related diseases.
Career Highlights
Hidetoshi Amano is associated with Hisamitsu Pharmaceutical Company, Inc., where he has been instrumental in advancing research and development in the pharmaceutical sector. His innovative approach to drug formulation has contributed to the company's reputation for producing effective therapeutic agents.
Collaborations
Amano has collaborated with notable colleagues, including Kanji Noda and Akira Nakagawa. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical solutions.
Conclusion
Hidetoshi Amano's contributions to the field of antiallergic compounds highlight his role as a significant inventor in the pharmaceutical industry. His innovative work continues to pave the way for new treatments for allergy-related diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile